All Insights
Showing 1 - 12 of 491
Competition, antitrust and trade
Sustainability: The French Competition Authority outlines a competition law analytical framework for Citeo's ReUse project in informal guidance
On 4 February 2026, pursuant to the French Competition Authority's (the " FCA") notice on informal guidance in sustainability matters
Regulatory Outlook
Competition | UK Regulatory Outlook February 2026
Consultation launched on major competition regime reforms | New guidance consolidated on market interventions | What are the focus areas
ESG – Environmental, social and governance
ESG Knowledge Update | February 2026
Welcome to our Osborne Clarke ESG Knowledge Update, which offers a round-up of legal, regulatory and market news
Competition, antitrust and trade
The UK CMA updates its merger remedies guidance
The regulator may be more open to behavioural remedies, but only where it is satisfied they are effective and proportionate
Competition, antitrust and trade
Will there be a more streamlined UK merger control process?
The CMA's procedural overhaul offers merging parties more influence over timing and remedies, but whether it will shorten reviews remains
Competition, antitrust and trade
What does the Getty Images/Shutterstock decision tell business about how the CMA approaches mergers in the UK?
Competition and Markets Authority rejects Getty/Shutterstock remedies, despite focus on growth
Competition, antitrust and trade
UK government consults on major reforms to competition processes
The government's growth agenda underlies a set of sweeping and probably controversial proposals
Life Sciences and Healthcare
Draft EU medtech revisions adjust importer and distributor roles to support supply chain resilience
Digital obligations, leaner repackaging rules and new shortage reporting tools may evolve supply chain responsibilities
Life Sciences and Healthcare
Planned EU medtech changes and codified Helsinki procedure support consistent qualification and classification
EU coordination, expert panel opinions and targeted down classification are proposed to harmonise risk based outcomes
Life Sciences and Healthcare
EU drug agency to take broader coordinating role in devices and diagnostics in latest proposal
Expert panel support, shortage coordination and combined study procedures strengthen the EMA's oversight of devices
Regulatory Outlook
Competition | UK Regulatory Outlook January 2026
Digital markets | Merger remedies | Civil engineering | Regulatory action plan | Subsidy Control Act
Life Sciences and Healthcare
Proposed EU medtech laws seek more predictable and efficient notified body oversight
Structured dialogue, streamlined sampling, extended audits and SME‑friendly fees to reshape device conformity assessment
